tradingkey.logo
tradingkey.logo
Suchen

Tivic Health Systems Inc

TIVC
Zur Watchlist hinzufügen
1.400USD
0.0000.00%
Trading geöffnet ETKurse um 15 Minuten verzögert
2.92MMarktkapitalisierung
VerlustKGV TTM

Tivic Health Systems Inc

1.400
0.0000.00%

mehr Informationen über Tivic Health Systems Inc Unternehmen

Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.

Tivic Health Systems Inc Informationen

BörsenkürzelTIVC
Name des UnternehmensTivic Health Systems Inc
IPO-datumNov 11, 2021
CEOErnst (Jennifer)
Anzahl der mitarbeiter7
WertpapierartOrdinary Share
GeschäftsjahresendeNov 11
Addresse47685 Lakeview Blvd
StadtFREMONT
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94538
Telefon18882766888
Websitehttps://tivichealth.com/
BörsenkürzelTIVC
IPO-datumNov 11, 2021
CEOErnst (Jennifer)

Führungskräfte von Tivic Health Systems Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
32.69K
+28.89%
Ms. Sheryle J Bolton
Ms. Sheryle J Bolton
Independent Chairman of the Board
Independent Chairman of the Board
10.00K
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Mr. Michael K. Handley
Mr. Michael K. Handley
Chief Operating Officer and President of Tivic Biopharma
Chief Operating Officer and President of Tivic Biopharma
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
32.69K
+28.89%
Ms. Sheryle J Bolton
Ms. Sheryle J Bolton
Independent Chairman of the Board
Independent Chairman of the Board
10.00K
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Thu, May 7
Aktualisiert: Thu, May 7
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Avenue Capital Group
3.24%
Geode Capital Management, L.L.C.
2.81%
Sanctuary Advisors, LLC
1.95%
Marex Group plc
1.89%
3I Management LLC
1.50%
Andere
88.62%
Aktionäre
Aktionäre
Anteil
Avenue Capital Group
3.24%
Geode Capital Management, L.L.C.
2.81%
Sanctuary Advisors, LLC
1.95%
Marex Group plc
1.89%
3I Management LLC
1.50%
Andere
88.62%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
7.54%
Investment Advisor
3.80%
Individual Investor
2.26%
Research Firm
0.16%
Hedge Fund
0.05%
Andere
86.19%

Institutionelle Beteiligung

Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
23
362.58K
11.55%
+205.09K
2025Q4
22
224.75K
8.90%
+144.85K
2025Q3
22
44.96K
2.86%
+5.91K
2025Q2
32
112.57K
10.82%
+62.79K
2025Q1
32
1.24K
0.18%
-48.58K
2024Q4
34
288.82K
2.82%
-516.93K
2024Q3
32
301.13K
4.87%
-468.33K
2024Q2
32
639.36K
10.34%
+419.46K
2024Q1
34
88.08K
6.01%
-141.85K
2023Q4
34
75.33K
5.40%
-149.34K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Avenue Capital Group
101.64K
3.53%
+101.64K
--
Sep 30, 2025
Geode Capital Management, L.L.C.
7.73K
0.27%
--
--
Jan 31, 2026
Marex Group plc
40.94K
1.42%
+2.55K
+6.64%
Dec 31, 2025
3I Management LLC
47.05K
1.64%
+47.05K
--
Feb 21, 2026
Ernst (Jennifer)
32.69K
1.14%
+9.44K
+40.62%
Dec 26, 2025
Susquehanna International Group, LLP
14.64K
0.51%
+14.64K
--
Dec 31, 2025
Handley Michael K
8.82K
0.31%
+8.82K
--
Feb 18, 2026
Mehr Anzeigen

Verbundene ETFs

Name
Anteil
Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Datum
Ex-Dividendentag
Art
Verhältnis
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
KeyAI